Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979463014> ?p ?o ?g. }
- W2979463014 endingPage "e0222993" @default.
- W2979463014 startingPage "e0222993" @default.
- W2979463014 abstract "Artemisinin resistance is threatening global efforts for malaria control and elimination. Primaquine (PQ) and methylene blue (MB) are gametocytocidal drugs that can be combined with artemisinin-based combination therapy (ACT) to reduce malaria transmission, including resistant strains. Children (6–59 months) with uncomplicated falciparum malaria in Burkina Faso were treated with artesunate-amodiaquine (AS-AQ) and randomized to MB (15 mg/kg/day for 3 days) or PQ (0.25 mg/kg at day 2) with the aim to show non-inferiority of the MB regimen with regard to haematological recovery at day 7 (primary endpoint). MB-AS-AQ could not be shown to be non-inferior to PQ-AS-AQ (mean Hb difference between treatment groups on day 7 was -0.352, 95% CI -0.832–0.128, p = 0.0767), however, haemoglobin recovery following treatment was alike in the two study arms (day 7: mean 0.2±1.4 g/dl vs. 0.5±0.9 g/dl, p = 0.446). Occurrence of adverse events was similar in both groups, except for vomiting, which was more frequent in the MB than in the PQ arm (20/50 vs 7/50, p = 0.003). Adequate clinical and parasitological response was above 95% in both groups, but significantly more asexual parasites were cleared in the MB arm compared to the PQ arm already on day 1 (48/50, 96%, vs 40/50, 80%, p = 0.014). Moreover, P. falciparum gametocyte prevalence and density were lower in the MB arm than in the PQ arm, which reached statistical significance on day 2 (prevalence: 2/50, 4%, vs 15/49, 31%, p<0.001; density: 9.6 vs 41.1/μl, p = 0.024). However, it should be considered that PQ was given only on day 2. MB-ACT appears to be an interesting alternative to PQ-ACT for the treatment of falciparum malaria. While there is a need to further improve MB formulations, MB-ACT may already be considered useful to reduce falciparum malaria transmission intensity, to increase treatment efficacy, and to reduce the risk for resistance development and spread. Trial registration: ClinicalTrials.gov NCT02851108." @default.
- W2979463014 created "2019-10-18" @default.
- W2979463014 creator A5000784501 @default.
- W2979463014 creator A5014427777 @default.
- W2979463014 creator A5014962765 @default.
- W2979463014 creator A5016955565 @default.
- W2979463014 creator A5019037867 @default.
- W2979463014 creator A5027526478 @default.
- W2979463014 creator A5032284171 @default.
- W2979463014 creator A5033754121 @default.
- W2979463014 creator A5040346501 @default.
- W2979463014 creator A5042500496 @default.
- W2979463014 creator A5047859834 @default.
- W2979463014 creator A5051283740 @default.
- W2979463014 creator A5059600151 @default.
- W2979463014 creator A5086515092 @default.
- W2979463014 creator A5091529832 @default.
- W2979463014 date "2019-10-10" @default.
- W2979463014 modified "2023-10-18" @default.
- W2979463014 title "Safety and efficacy of artesunate-amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: A randomized controlled trial" @default.
- W2979463014 cites W1573174442 @default.
- W2979463014 cites W1631305139 @default.
- W2979463014 cites W1750873442 @default.
- W2979463014 cites W1891572011 @default.
- W2979463014 cites W1965599026 @default.
- W2979463014 cites W1984750426 @default.
- W2979463014 cites W2015821148 @default.
- W2979463014 cites W2035992308 @default.
- W2979463014 cites W2058689460 @default.
- W2979463014 cites W2090336622 @default.
- W2979463014 cites W2093992883 @default.
- W2979463014 cites W2101792514 @default.
- W2979463014 cites W2105812381 @default.
- W2979463014 cites W2106549778 @default.
- W2979463014 cites W2139477348 @default.
- W2979463014 cites W2146883638 @default.
- W2979463014 cites W2149647811 @default.
- W2979463014 cites W2783246805 @default.
- W2979463014 cites W2785868810 @default.
- W2979463014 cites W2800120410 @default.
- W2979463014 cites W3189355562 @default.
- W2979463014 cites W4211090760 @default.
- W2979463014 cites W4211099777 @default.
- W2979463014 cites W4211101162 @default.
- W2979463014 cites W4252155475 @default.
- W2979463014 cites W4300811467 @default.
- W2979463014 cites W612972800 @default.
- W2979463014 doi "https://doi.org/10.1371/journal.pone.0222993" @default.
- W2979463014 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6786573" @default.
- W2979463014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31600221" @default.
- W2979463014 hasPublicationYear "2019" @default.
- W2979463014 type Work @default.
- W2979463014 sameAs 2979463014 @default.
- W2979463014 citedByCount "15" @default.
- W2979463014 countsByYear W29794630142020 @default.
- W2979463014 countsByYear W29794630142021 @default.
- W2979463014 countsByYear W29794630142022 @default.
- W2979463014 countsByYear W29794630142023 @default.
- W2979463014 crossrefType "journal-article" @default.
- W2979463014 hasAuthorship W2979463014A5000784501 @default.
- W2979463014 hasAuthorship W2979463014A5014427777 @default.
- W2979463014 hasAuthorship W2979463014A5014962765 @default.
- W2979463014 hasAuthorship W2979463014A5016955565 @default.
- W2979463014 hasAuthorship W2979463014A5019037867 @default.
- W2979463014 hasAuthorship W2979463014A5027526478 @default.
- W2979463014 hasAuthorship W2979463014A5032284171 @default.
- W2979463014 hasAuthorship W2979463014A5033754121 @default.
- W2979463014 hasAuthorship W2979463014A5040346501 @default.
- W2979463014 hasAuthorship W2979463014A5042500496 @default.
- W2979463014 hasAuthorship W2979463014A5047859834 @default.
- W2979463014 hasAuthorship W2979463014A5051283740 @default.
- W2979463014 hasAuthorship W2979463014A5059600151 @default.
- W2979463014 hasAuthorship W2979463014A5086515092 @default.
- W2979463014 hasAuthorship W2979463014A5091529832 @default.
- W2979463014 hasBestOaLocation W29794630141 @default.
- W2979463014 hasConcept C126322002 @default.
- W2979463014 hasConcept C168563851 @default.
- W2979463014 hasConcept C203014093 @default.
- W2979463014 hasConcept C203092338 @default.
- W2979463014 hasConcept C2776120307 @default.
- W2979463014 hasConcept C2776793103 @default.
- W2979463014 hasConcept C2776992834 @default.
- W2979463014 hasConcept C2777425658 @default.
- W2979463014 hasConcept C2777616469 @default.
- W2979463014 hasConcept C2778048844 @default.
- W2979463014 hasConcept C2778059366 @default.
- W2979463014 hasConcept C2778371730 @default.
- W2979463014 hasConcept C2780852908 @default.
- W2979463014 hasConcept C2781413609 @default.
- W2979463014 hasConcept C71924100 @default.
- W2979463014 hasConcept C90924648 @default.
- W2979463014 hasConcept C98274493 @default.
- W2979463014 hasConcept C99389464 @default.
- W2979463014 hasConceptScore W2979463014C126322002 @default.
- W2979463014 hasConceptScore W2979463014C168563851 @default.
- W2979463014 hasConceptScore W2979463014C203014093 @default.
- W2979463014 hasConceptScore W2979463014C203092338 @default.
- W2979463014 hasConceptScore W2979463014C2776120307 @default.